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ABSTRACT
Mismatch repair (MMR) enzymes have been shown to be deficient in prostate 
cancer (PCa). MMR can influence the regulation of tumor development in various 
cancers but their role on PCa has not been investigated. The aim of the present study 
was to determine the functional effects of the mutL-homolog 1 (MLH1) gene on 
growth of PCa cells. The DU145 cell line has been established as MLH1-deficient and 
thus, this cell line was utilized to determine effects of MLH1 by gene expression. Lack 
of MLH1 protein expression was confirmed by Western blotting in DU145 cells whereas 
levels were high in normal PWR-1E and RWPE-1 prostatic cells. MLH1-expressing 
stable transfectant DU145 cells were then created to characterize the effects this MMR 
gene has on various growth properties. Expression of MLH1 resulted in decreased 
cell proliferation, migration and invasion properties. Lack of cell growth in vivo also 
indicated a tumor suppressive effect by MLH1. Interestingly, MLH1 caused an increase 
in apoptosis along with phosphorylated c-Abl, and treatment with MLH1 siRNAs 
countered this effect. Furthermore, inhibition of c-Abl with STI571 also abrogated 
the effect on apoptosis caused by MLH1. These results demonstrate MLH1 protects 
against PCa development by inducing c-Abl-mediated apoptosis.
INTRODUCTION
Prostate cancer (PCa) is the most frequently 
diagnosed malignancy and the second leading cause of 
cancer death among males in the United States [1]. It is 
estimated that in 2014, there will be 233,000 new cases 
and 29,480 deaths due to PCa [1]. PCa is a disease of 
aging as 1 in 43 of those aged 50 to 59, 1 in 16 aged 60 
to 69, and 1 in 9 aged 70 years and older will develop 
invasive disease [1]. Most cases of PCa are treatable with 
androgen-deprivation therapy however the majority of PCa 
recur as androgen-independent, metastatic disease that 
leads to death within several years. Currently, no effective 
therapies are available to cure androgen-independent PCa. 
Thus, new prognostic markers and effective treatment 
strategies are urgently needed.
A factor that may prevent the prostate carcinogenesis 
process is the DNA mismatch repair (MMR) system 
that consists of various types of proteins such as the 
MutS homologues and MutL homologues (MLH) [2, 
3]. Defects in this MMR pathway result in an increased 
rate of mutation or genetic instability, which in turn leads 
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to defects in genes that regulate cell proliferation and 
death [4], thereby increasing susceptibility to cancers. 
Alternatively, MMR genes have also been shown to 
sensitize cells toward DNA lesions and trigger apoptosis, 
cell cycle arrest, and cell death [5, 6]. Thus, MMR is 
essential for proper cellular function and health of the 
individual.
Clinical case reports have shown that PCa can occur 
in men afflicted with hereditary non-polyposis colorectal 
cancer (HNPCC), a disease known for mutations in MMR 
[7, 8]. The cumulative lifetime risk of PCa was calculated 
to be two-fold higher among individuals with HNPCC and 
defective MMR as compared to the general population 
[8]. In a study by Grindedal et al [9], nine individuals 
contracted PCa among a cohort of 106 Norwegian men 
described as carriers or obligate carriers of MMR mutation 
and this rate was much higher than the 1.52 expected to 
occur by chance in the Norwegian population (P < 0.01). 
These men were younger at the time of diagnosis (60.4 
years vs. 66.6 years, P = 0.006) and had higher Gleason 
scores of 8 to 10 compared to men diagnosed prior to 70 
years of age in the population (P < 0.00001). Kaplan-
Meier analysis revealed that the cumulative risk of 
PCa diagnosis by age 70 years was 30% in MMR gene 
mutation carriers compared to 8% in the population. Thus 
MMR imperfections can lead to PCa.
Among the various MMR genes, hundreds of 
mutations and polymorphisms have been identified and 
interestingly, most of these variants are observed in the 
MLH1 gene (50%), thus making this a highly susceptible 
gene in the carcinogenesis process [10]. Defects in MLH1 
have been documented in various cultured prostate cell 
lines. Among the first reports was the PCa line DU145 
where Boyer et al [11] identified a mutation in the MLH1 
gene after demonstrating reduced MMR activity and 
microsatellite instability. Chen et al [12] confirms genomic 
instability in DU145 cells where MLH1 protein expression 
was lacking. A prior study from our laboratory [13] show 
the DU145, LNCaP, and PC3 PCa cell lines to have much 
lower levels of MLH1 protein expression and these all had 
reduced DNA repair activity as compared to the MMR 
proficient Hela cells. 
MLH1 expression has also been studied in prostate 
tissue. A report by Chen et al [12] found that in the normal 
prostate gland, MLH1 protein was predominantly detected 
in the nuclei of glandular luminal epithelium, basal cells, 
and some stromal cells. This pattern of MLH1 expression 
was also observed in the normal adjacent region of 
prostate tumor tissue. In malignant prostate cells however, 
MLH1 levels were found to be less than that observed in 
normal adjacent areas. Other studies also show reduced 
MLH1 protein expression in prostate tumor regions as 
compared to normal adjacent [14, 15]. Additionally, 
MLH1 expression was found to be much lower in PCa 
when compared to benign prostatic hyperplasia tissue [15]. 
The MLH1 gene is thus shown to be reduced 
in PCa cell lines and tissues. Therefore in this report, 
we characterize the functional role the MLH1 gene 
plays in PCa cells. Our results are the first to show 
that re-expressing the MLH1 gene in PCa cells causes 
inhibition of cell growth both in vitro and in vivo. Also, 
we demonstrate MLH1 to enhance apoptosis and induce 
phosphorylation of the c-Abl protein as a mechanism for 
its protective role in PCa cells.
RESULTS:
Prostate cancer cell line DU145 is MLH1 deficient
Prior studies have established DU145 cells to 
be MLH1-deficient [12, 13] and thus, we selected this 
cancerous cell line for further studies. Initially, we 
confirmed protein and RNA expression levels of MLH1 
in DU145 cells and as a comparison, measured expression 
in the normal prostate epithelial cell lines, PWR-1E 
and RWPE-1. Figure 1A shows no protein detected and 
1B significantly reduced RNA expression for MLH1 in 
Figure 1: MLH1 expression is downregulated in 
DU145 PCa cells. Prostatic cell lines were grown in culture 
dishes for two days. (A) Representative immunoblot displaying 
MLH1 protein expression in DU145 and normal prostate 
epithelial PWR-1E and RWPE-1 cells. GAPDH was used as 
loading control. (B) Relative mRNA expression levels of MLH1 
in cell lines as determined by real-time PCR. Expression levels 
are normalized to PWR-1E. Data are presented as mean±SEM 
of three experiments. Asterisks denote differences between the 
compared values: *P<0.05, **P<0.01. 
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DU145 cells whereas levels were high in both PWR-1E 
(P<0.01) and RWPE-1 (P<0.05).
Effect of MLH1 re-expression on cell 
proliferation, migration and invasion
Absence of MLH1 protein in DU145 cells led us to 
examine whether re-expressing MLH1 affects the growth 
of these cells. To do this, we established a DU145 cell 
line that stably expresses MLH1. As shown in Figure 2A, 
MLH1 protein was detected by Western blotting in stable 
MLH1-transfected DU145 cells but not in mock or vector 
control cells. To determine the effects of MLH1 on cellular 
properties, we conducted various functional analyses. 
MTS assay show that cell proliferation was reduced over 
30% after 48 hours in DU145 cells expressing MLH1 
compared to vector control (P<0.01) (Figure 2B). Wound 
healing assay demonstrated significant inhibition of 
cell migration in MLH1-stable compared with vector-
transfected DU145 cells after 24 hours (73% versus 89% 
closure, respectively, P<0.01) (Figure 2C). Matrigel 
invasion assay also show that the number of invading 
cells was significantly decreased in MLH1 transfectants 
with absorbance at 560 nm of 0.22 compared with vector 
control having absorbance of 0.28 (P<0.01) (Figure 2D). 
These results indicate MLH1 to play an important role in 
reducing tumor cell proliferation, migration and invasion. 
Figure 2: Re-expression and tumor suppressive effect of MLH1 on DU145 cells. (A) Ectopic expression of MLH1. DU145 
cells stably transfected with either MLH1 or empty vector (pCMV) along with mock (parental DU145 cells treated with transfection 
reagent alone) were grown for 48 hours and underwent Western analyses. GAPDH was used as loading control. (B) Cell proliferation as 
analyzed by the MTS cell proliferation assay 48 hours after plating cells. Results are expressed as % and normalized to pCMV control. 
(C) Cell migration as measured by wound healing assay. A wound was formed by scraping culture dishes using a pipet tip and closure 
measured after 24 hours. Left: Representative images of wound healing assay are shown. Right: Migration expressed as % closure of 
wound. (D) Cell invasiveness as measured using Matrigel. Cells were placed onto transwell membrane and allowed to invade for 24 hours. 
Left: Representative images of invading cells are shown. Right: Cell invasiveness as measured by absorbance (Abs) at 560 nm. Data are 
presented as mean±SEM of at least three experiments; **P<0.01 MLH1 versus pCMV.
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Effect of MLH1 expression on tumorigenicity in 
vivo
To validate the suppressive effect of MLH1 under 
in vitro conditions, we also determined effects of MLH1 
on tumor growth in animal models. Stable MLH1 and 
pCMV DU145 cells were subcutaneously injected 
into nude mice. We observed that expression of MLH1 
inhibited DU145 cell tumor formation throughout the 
duration which lasted 5 weeks whereas by week 4, tumor 
growth was visible in pCMV animals. By week five, tumor 
sizes were dramatically increased to an average of 565 
mm3 in controls compared to 13 mm3 in MLH1-treated 
mice (P<0.05) (Figure 3). These results suggest MLH1 
suppresses PCa cell growth in vivo.
MLH1 influences cellular apoptosis
Since MLH1 restoration significantly inhibits cell 
growth and progression of DU145 cells both in vitro and 
in vivo, we hypothesized that its expression may induce 
apoptosis. Figure 4A shows that the apoptotic and early 
apoptotic fractions (upper right and lower right quadrants 
of biparametric histograms, respectively) were increased 
in MLH1-transfectants compared to vector control after 48 
and 72 hours of growth. Total apoptosis levels were 10.3% 
versus 15.7% at 48 hours (P<0.05) and 14.6% versus 
26.0% at 72 hours (P<0.05) for pCMV versus MLH1-
expressing cells, respectively (Figure 4A).
MLH1 induces c-Abl phosphorylation
The pro-apoptotic role for MLH1 observed suggests 
that apoptotic pathways are affected. It has been reported 
that c-Abl mediates MLH1-dependent apoptosis in other 
cell types such as colon cancer cells [16]. Therefore, 
we examined the expression of c-Abl in DU145 cells 
and found that phosphorylated c-Abl protein was up-
regulated in MLH1-transfectants whereas levels of the 
non-phosphorylated form was not changed (Figure 4B). 
Additionally, we found that MLH1 expression caused 
an increase in cleaved PARP which further supports the 
pro-apoptotic role of MLH1. These results indicate c-Abl 
phosphorylation to moderate the apoptotic effects of 
MLH1 in PCa cells.
Inhibition of MLH1 prevents apoptotic cell death 
in MLH1-expressing cells
To establish MLH1 as a key effector in the c-Abl-
mediated apoptotic signaling pathway, we measured 
apoptotic cell death by exploiting siRNA to selectively 
knock down MLH1 (siMLH1) in MLH1-stable DU145 
cells. We first confirmed the ability of siMLH1 to 
suppress endogenous MLH1 levels. Administration of 
three MLH1 siRNAs to MLH1-expressing DU145 cells 
decreased both basal MLH1 mRNA (data not shown) and 
protein (Figure 5A) expression. Interestingly, all three 
siMLH1s also significantly reduced apoptosis (siMLH1-1 
(4.6%, P<0.01), siMLH1-2 (3.6%, P<0.01), siMLH1-3 
(6.4%, P<0.05) compared to siRNA negative control 
(10.1%) (Figure 5B). Furthermore, MLH1 knockdown 
Figure 3: Expression of MLH1 suppresses growth of DU145 cells in vivo. Athymic nude mice were injected subcutaneously 
with stable MLH1 or pCMV-transfected DU145 cells and growth monitored over time. Left: Representative image of tumors in mice five 
weeks after injection of cells. Right: Growth of tumor size plotted over time. Data are presented as mean±SEM of five mice per group; 
*P<0.05 MLH1 versus pCMV for each time point.
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Figure 4: MLH1 expression upregulates apoptosis and phosphorylated c-Abl (p-c-Abl). Stable MLH1-expressing and 
vector control DU145 cells were grown over time. (A) Apoptosis as measured by flow cytometric analyses. Representative biparametric 
histogram showing cell population in early (bottom right quadrant) and late (top right quadrant) apoptotic, and viable (bottom left quadrant) 
states. Left: pCMV control, Middle: MLH1-expressing, Right: Total apoptosis %, Upper: 48 hours of growth, Lower: 72 hours of growth. 
Bar graph of total apoptosis % is presented as mean±SEM of three experiments, *P<0.05 MLH1 versus pCMV. (B) Protein levels of MLH1, 
cleaved PARP (cl-PARP), c-Abl, and p-c-Abl were determined by Western blot analyses after growing pCMV and MLH1 cells for 48 hours. 
GAPDH was used as loading control.
Figure 5: MLH1 knockdown reduces phosphorylated c-Abl (p-c-Abl) and apoptosis. Three MLH1 siRNAs (siMLH1s) 
were transfected individually along with a non-specific siRNA control (siControl) into stable MLH1-expressing DU145 cells for 48 hours. 
pCMV control cells treated with Lipofectamine are also included. (A) Protein levels of MLH1, c-Abl, and p-c-Abl in cells as determined by 
Western blot analyses. GAPDH was used as loading control. (B) Total apoptotic cells were analyzed by flow cytometry. Data are expressed 
as mean±SEM of three experiments; *P<0.05 **P<0.01 siMLH1s versus siControl. 
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decreased phosphorylation of c-Abl without affecting non-
phosphorylated c-Abl protein levels (Figure 5A). These 
results demonstrate that MLH1 induces apoptosis by c-Abl 
phosphorylation in PCa cells.
Inhibition of c-Abl prevents apoptotic cell death 
in MLH1-expressing cells
To confirm the role of c-Abl as a regulator of MLH1-
stimulated apoptosis, we examined the effect of the c-Abl 
inhibitor, STI571. MLH1 causes apoptosis in DU145 
cells but when treated with STI571, a marked decrease of 
apoptosis to vector control levels was observed in MLH1-
expressing cells (P<0.01) (Figure 6). We also observe 
phosphorylated c-Abl to be reduced due to STI571 (data 
not shown). These results further demonstrate that c-Abl 
regulates apoptosis in MLH1-expressing DU145 PCa 
cells.
DISCUSSION
The MMR system recognizes and corrects mis-
incorporated nucleotides and insertion/deletion mis-pairs 
formed during DNA replication [2, 3]. Loss of proteins 
critical in this repair process however, can result in 
genetic alterations that may ultimately lead to cancer. 
MMR deficiency also predisposes cells of the body to an 
increased frequency of inactivating mutations in genes 
important for suppressing carcinogenesis [4]. Besides 
their established role in DNA repair, MMR genes are also 
involved in cell cycle checkpoints and apoptosis stimulated 
by DNA damage [5, 6]. Resistance to apoptosis and cell 
death were shown in cells deficient in MMR genes when 
treated with DNA damaging chemotherapeutic agents [17, 
18]. The MMR system is thus vital for maintaining cell 
integrity and disease prevention.
Among the various MMR genes, MLH1 has been 
shown to be among the most essential in sensitizing cells 
to undergo apoptosis [19]. This gene has also been shown 
to be more prone to mutation [10]. The genetic status of 
MLH1 in cells thus has high impact in cellular function. 
The MLH1 gene is located in chromosome 3p21 region, 
consists of 19 exons and is roughly 58 kilobases in length 
[20]. MLH1 is a nuclear protein that consists of 756 amino 
acids with a size of 80 kDa.
In prostate tissues, MLH1 has been shown to be 
downregulated in tumor regions as compared to normal 
prostate [12], normal adjacent regions [12, 14, 15] and 
benign hyperplasia [15]. Given that MLH1 can affect cell 
growth parameters, we explored the functional significance 
the MLH1 gene has on PCa cells which has never been 
done. MLH1 protein expression in the DU145 cell line has 
previously been shown to be downregulated [12, 13] and 
our results confirm this lack of protein expression. This 
reduction is apparently due to a truncation in the MLH1 
gene caused by a premature stop codon as observed by 
Chen et al [12]. These investigators discovered a loss of 5 
nucleotides at the start of the coding region of exon 2 that 
results in a frameshift producing a TGA stop at codon 39. 
Additionally, we observed that RNA levels are reduced 
in this cell line which indicates that the transcriptional 
machinery in DU145 cells is also affected. Thus, DU145 
PCa cells are an ideal cell line to determine functional 
effects of the MLH1 gene by re-expression.
By expressing the MLH1 gene in DU145 cells, we 
observed that this gene caused a significant reduction 
in proliferation, migration, and invasive properties of 
this PCa cell line. A similar effect was observed in vivo 
as MLH1-expressing cells inhibited cell growth. This 
repressive activity was found to be due to apoptosis as 
MLH1 cells had a much higher rate compared to that 
of vector control. The apoptotic environment was also 
Figure 6: Inhibition of c-Abl nullifies MLH1-triggered apoptotic effect. MLH1-expressing and pCMV control DU145 
transfectants were treated with either DMSO or STI571 and maintained for 48 hours. Total apoptotic cells were then analyzed by flow 
cytometry. Data are expressed as mean±SEM of three experiments; **P<0.01 MLH1+/STI571+ versus MLH1+/STI571-.
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supported by an observed rise in cleaved PARP, suggesting 
the presence of caspases [21, 22]. On the contrary, 
silencing MLH1 in normal prostatic PWR-1E cells caused 
an increase in proliferation for two of three siMLH1 
treatments (Supplementary Figure 1). Thus, MLH1 plays 
a tumor suppressor role in PCa cells. In concordance with 
our results, MLH1 has been shown by others to play an 
important role in apoptosis and cell cycle control [5, 6, 
23]. In MLH1-deficient HCT116 colon cancer cells, 
expressing MLH1 by injecting chromosome 3 led to 
growth arrest whereas parental HCT116 or HCT116 cells 
injected with chromosome 2 had no effect after treatment 
with methylnitronitrosoguanidine (MNNG) [24]. Hawn 
et al [25] finds these HCT116+chromosome 3 cells to be 
arrested at G2 phase after treatment with 6-thioguanine 
or MNNG. In the ovarian cancer cell line A2780MNU1 
that is MMR deficient, re-expression of MLH1 by 
gene transfection resulted in marked reductions of cell 
survival and proliferation, with higher percentage of cells 
displaying active caspase 3 after drug treatment [26]. In a 
report by Zhang et al [19], MLH1 cDNA was expressed 
in HCT116 and they find apoptosis to be increased nearly 
3-fold. Also, Ruzov et al [27] observes that expressing 
MLH1 causes apoptosis in HCT116 cells as well as during 
the onset of gastrulation in embryos.
The mechanism by which MLH1 induces apoptosis 
thereby protecting against tumor formation is not fully 
understood. There are several studies that establish the 
c-Abl protein as a mediator in the MLH1-dependent 
cellular response to damage [16, 28-30]. Therefore in 
this study, we investigated whether c-Abl plays a crucial 
role in the MLH1-induced apoptotic response in PCa 
cells. We demonstrate phosphorylation of c-Abl to be a 
key component in MLH1-triggered apoptosis in DU145 
cells as knockdown of c-Abl with the inhibitor STI571 
abrogated the apoptotic effect in these cells. Also, 
the phosphorylated form of c-Abl is necessary as no 
differences were detected with the non-phosphorylated 
form between treatment groups. It is noteworthy to point 
out however, that although siMLH1 efficiently reduced 
MLH1 expression to pCMV levels, phosphorylated 
c-Abl was reduced but not to the same effect. This may 
be due to the fact that siMLH1 treatment started during 
the growth phase and cells had already accumulated 
phosphorylated c-Abl to an extent. This is further 
corroborated by the observation that apoptosis was also 
dramatically reduced but not to that of pCMV levels by all 
three siMLH1 treatments. The phosphorylation of c-Abl is 
thus critical for its activation and has been shown to occur 
at tyrosine sites [31, 32]. Further, our antibody detects 
phosphorylation at tyrosine-204 of the SH2 domain 
and studies show phosphorylation of this core region 
of c-Abl to impact protein conformation and signaling 
[33]. The process by which c-Abl is phosphorylated is 
not known. Studies have shown that activation of c-Abl 
is dependent on the ataxia telangiectasia mutated (ATM) 
gene [34, 35]. In a study by Baskaran et al [35], ATM was 
required to activate c-Abl and was due to phosphorylation 
at serine-465. Interestingly, a feedback for activation 
between these molecules was also observed [36]. 
The dependence of c-Abl in the MLH1 signaling 
pathway is in agreement with others as Li et al [16] 
observed MLH1-expressing cells to cause apoptosis in 
a p53-independent manner but when treating cells with 
STI571 or creating stable c-Abl knockdown transfectants, 
MLH1-dependent apoptosis was prevented. These authors 
further show the MLH1/c-Abl downstream effectors 
p73α and GADD45α to be of importance in the apoptotic 
pathway. In a report by Kim et al [29], MLH1 was also 
found to trigger the MEKK-1/MKK4/JNK/c-jun pathway 
in response to DNA damage. Interestingly, they find 
that c-Abl is required to activate this signaling cascade 
by MLH1. In fact, they observe a functional interacting 
complex between MLH1 and c-Abl. Thus although 
it is apparent that MLH1 affects alternative signaling 
pathways, evidence strongly suggests that c-Abl is a 
critical mediator for the MLH1-induced response.
In summary, this is the first report that shows 
MLH1 to display a protection against PCa by inhibiting 
cell proliferation, migration, and invasion in vitro as well 
as tumor growth in vivo. MLH1 induced apoptosis and 
was dependent on phosphorylation of c-Abl. Thus, we 
conclude that phosphorylated c-Abl plays a key role in the 
tumor suppressive effect of the MLH1 signaling pathway 
in prostate cells.
MATERIALS AND METHODS
Cell lines and reagents
Human PCa cell line DU145 and non-malignant 
epithelial prostate cell lines PWR-1E and RWPE-1 
were purchased from American Type Culture Collection 
(Manassas, VA). Keratinocyte serum-free medium, bovine 
pituitary extract and human recombinant epidermal 
growth factor were purchased from Invitrogen (Carlsbad, 
CA). RPMI 1640, Opti-minimum essential medium and 
penicillin/streptomycin were obtained from the UCSF 
Cell Culture Facility (San Francisco, CA). Fetal bovine 
serum (FBS) was a product of Atlanta Biologicals 
(Lawrenceville, GA). 
Cell culture
DU145 cells were cultured in RPMI 1640 medium 
supplemented with 10% FBS. PWR-1E and RWPE-
1 cells were cultured in keratinocyte growth medium 
supplemented with 5 ng/mL human recombinant epidermal 
growth factor and 0.05 mg/mL bovine pituitary extract. 
All cell lines were maintained at 37°C in a humidified 
Oncotarget11304www.impactjournals.com/oncotarget
atmosphere composed of 5% CO2 and 95% air. 
Western blot analysis
Whole cell extracts from cultured cells were 
prepared using radioimmunoprecipitation assay buffer 
(Thermo Scientific, Rockford, IL) containing protease 
inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). 
Protein quantification was done using a BCA protein assay 
kit (Thermo Scientific) according to the manufacturer’s 
instructions. Total protein (20 μg) was loaded onto 4-12% 
bis–tris gels with 3-(N-morpholino) propanesulfonic acid 
buffer and separated by a NuPAGE electrophoresis system 
(Invitrogen). Protein was transferred to Invitrogen™ 
polyvinylidene difluoride and immunoblotting was 
carried out according to standard protocols. Monoclonal 
antibodies against MLH1, cleaved PARP, c-Abl, and 
phosphorylated c-Abl were purchased from Cell Signaling 
(Danvers, MA) and monoclonal antibody against 
GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA) 
was used to confirm equal loading. The membrane was 
washed and then incubated with secondary antibodies 
conjugated to horseradish peroxidase (Cell Signaling 
Technology). Protein complexes were visualized with 
the Echo-chemiluminescence (ECL) Detection System 
(GE Healthcare, Little Chalfont, UK) using the Chemidoc 
Imaging System (Bio-Rad Laboratories, Hercules, CA). 
RNA extraction
Total RNA was extracted from DU145, PWR-
1E and RWPE-1 cells using the RNeasy Mini kit 
(Qiagen, Valencia, CA) according to the manufacturer’s 
instructions.
Quantitative reverse transcription–polymerase 
chain reaction
Extracted RNA was reverse-transcribed into 
complementary DNA (cDNA) using iScript cDNA 
Synthesis kit (Bio-Rad) and TaqMan MicroRNA Reverse 
Transcription kit (Applied Biosystems, Foster City, CA). 
Quantitative real-time PCR analysis was performed 
with an Applied Biosystems Prism 7500 Fast Sequence 
Detection System using TaqMan Universal PCR master 
mix according to the manufacturer’s protocol (Applied 
Biosystems). Levels of RNA expression were determined 
using the 7500 Fast System SDS software version 1.3.1 
(Applied Biosystems). PCR parameters for cycling were 
as follows: 95°C for 20 seconds, then 40 cycles of 95°C 
for 3 seconds and 60°C for 30 seconds. All reactions were 
done in a 10 μL reaction volume in triplicate. The data 
were analyzed using the delta-delta Ct method to calculate 
the fold-change. TaqMan probes and primers for MLH1 
(assay ID: Hs00179866_m1) and GAPDH (assay ID: 
Hs02758991_g1) were obtained from Applied Biosystems. 
GAPDH was used as internal control. 
Establishment of DU145 cells stably expressing 
MLH1
DU145 cells were transfected with pCMV6-ENTRY 
vector expressing the C-terminally Myc and Flag-tagged 
human MLH1 cDNA as well as empty pCMV6-ENTRY 
vector as a control (OriGene Techologies, Rockville, 
MD) using X-treme Gene HD transfection reagent 
(Roche Diagnostics, Indianapolis, IN) according to the 
manufacturer’s protocol. Clones were selected using 500 
μg/ml of G418 (Invitrogen). Colonies resistant to G418 
appeared within 2 weeks and single colonies were picked 
and then expanded for another 3 weeks to make stable 
clone stock cells. 
Cell proliferation assay
An MTS based assay was utilized to determine 
cell proliferation. Cells were plated in triplicate in 96-
well microplates at a density of 5 × 103 cells per well. 
At the desired time point, the number of viable cells 
was determined by adding CellTiter 96 AQueous One 
Solution reagent (Promega, Madison, WI) to each well and 
measuring the absorbance at 490 nm on a SpectraMax 190 
plate reader (Molecular Devices, Sunnyvale, CA). Results 
were expressed as the percentage of optical density with 
absorbance of control cells being 100%. 
Migration and Invasion assays
Cell migration was evaluated by a wound-healing 
assay. Cells were plated in six-well dishes and monolayers 
were scraped using a P-20 micropipette tip. The width of 
the initial gap (0 hour) and the residual gap 24 hours after 
wounding were calculated from photomicrographs taken 
using a Nikon Eclipse TS100 microscope (Technical 
Instruments, Burlingame CA). Cell invasion properties 
were measured by a procedure using the CytoSelect 
Invasion assay (Cell Biolabs, San Diego CA) along with 
modified Boyden chambers consisting of transwell-
precoated Matrigel membrane filter inserts with eight 
micron pores in 24-well tissue culture plates (BD 
Biosciences, Bedford, MA). Minimum essential medium 
containing 10% FBS in the lower chamber served as the 
chemo-attractant. After 24 hours, invasive cells were 
stained and observed by photomicrographs taken with the 
Nikon microscope and quantified using the SpectraMax 
plate reader at absorbance of 560 nm.
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In vivo tumor growth
All animal care was in accordance with the 
guidelines and this study was approved by the San 
Francisco Veterans Affairs IACUC (Institutional Animal 
Care and Use Committee). Animal users completed 
training programs to handle and work with mice 
through AALAS (American Association for Laboratory 
Animal Science) prior to animal experiments. For the 
subcutaneous xenograft mouse model, DU145 cells (5 
x 106) stably transfected with MLH1 or empty pCMV6-
ENTRY vector were suspended in 100 μL RPMI 1640 
medium and subcutaneously injected into the right 
backside flank of five week old female nude mice (strain 
BALB/c nu/nu; Charles River Laboratories, Wilmington, 
MA). Five nude mice were used per treatment group and 
tumor growth was examined over the course of 35 days. 
Tumor volume was calculated on the basis of width (x) 
and length (y) using the formula: x2y/2, where x<y.
Apoptosis assay
Apoptosis was analyzed with an annexin 
V-fluorescein isothiocyanate (FITC)/7-amino-actinomycin 
D staining system obtained from BD Biosciences (San 
Diego, CA). Briefly, prostate cells were harvested and 
resuspended in binding buffer at a concentration of 1 × 106 
cells/ml. For each assay, 1 × 105 cells were incubated with 
5 μl of annexin V-FITC and 5 μl of 7-amino-actinomycin 
D in the dark for 15 min at room temperature. After adding 
400 μl of binding buffer, samples were analyzed within 
an hour by a Cell Lab Quanta™ SC MPL flow cytometer 
(Beckman Coulter, Fullerton, CA). 
Small interfering RNA transfection
Cells grown to 30–50% confluence were treated 
with three different sets of small interfering RNA (siRNA) 
duplexes specific for human MLH1 (siMLH1) or universal 
scrambled negative control (OriGene Techologies) by 
transfection using Lipofectamine 2000 transfection 
reagent (Invitrogen) as described by the manufacturer. 
Knockdown efficiency was evaluated by both real-
time PCR and Western blotting for the three siMLH1s 
at different concentrations and the optimal condition 
selected was 30 nM. Vector control cells treated with 
Lipofectamine alone was also included.
STI571 treatment
pCMV and MLH1-transfected DU145 cells were 
grown in six-well plates. After two days, cells were treated 
with either 10 μM STI571 (via Fisher Scientific, Pittsburg 
PA) or dimethylsulfoxide (DMSO) diluent (Sigma-
Aldrich, St Louis MO). Cells were then allowed to grow 
for another two days and harvested to determine apoptosis 
as described above.
Statistical analysis
Values in Figures are presented as the 
mean±standard error of mean (SEM) based on results 
obtained from at least three independent experiments. For 
in vivo studies, results are based on five animals per group. 
The relationship between variables was analyzed using 
the non-parametric Mann-Whitney U test or two-tailed 
Student’s t-test. All analyses were performed using Expert 
StatView (version 4, SAS Institute, Cary, NC).
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